Vonoprazan and amoxicillin dual therapy as the first‐line treatment of Helicobacter pylori infection: A systematic review and meta‐analysis

医学 阿莫西林 内科学 幽门螺杆菌 不利影响 科克伦图书馆 荟萃分析 胃肠病学 随机对照试验 抗生素 微生物学 生物
作者
Ren‐Chun Du,Yuxin Hu,Yaobin Ouyang,Li‐Xiang Ling,Jing‐Yuan Xu,Rina Sa,Xiao‐Shun Liu,Junbo Hong,Yin Zhu,Nonghua Lü,Yi Hu
出处
期刊:Helicobacter [Wiley]
卷期号:29 (1) 被引量:23
标识
DOI:10.1111/hel.13039
摘要

Abstract Background Recent clinical trials have evaluated the efficacy of vonoprazan‐amoxicillin (VA) dual therapy as the first‐line treatment for Helicobacter pylori infection in different regions with inconsistent results reported. In this systematic review and meta‐analysis, we aimed to evaluate the efficacy of VA dual therapy compared to the currently recommended therapy for eradicating H. pylori . Materials and Methods A comprehensive search of the PubMed, Cochrane, and Embase databases was performed using the following search terms: (“ Helicobacter ” OR “ H. pylori ” OR “ Hp ”) AND (“vonoprazan” OR “potassium‐competitive acid blocker” OR “P‐CAB”) AND (“amoxicillin” OR “penicillin”) AND (“dual”). The primary outcome was to evaluate the eradication rate according to intention‐to‐treat and per‐protocol analysis. The secondary outcomes were adverse events and compliance. Results A total of 15 studies involving 4, 568 patients were included. The pooled eradication rate of VA dual therapy was 85.0% and 90.0% by intention‐to‐treat and per‐protocol analysis, respectively. The adverse events rate and compliance of VA dual therapy were 17.5% and 96%, respectively. The efficacy of VA dual therapy was superior to proton pump inhibitors‐based triple therapy (82.0% vs. 71.4%, p < 0.01) but lower than vonoprazan‐containing quadruple therapy (83.1% vs. 93.3%, p = 0.02). 7‐day VA dual therapy showed lower eradication rates than 10‐day (χ 2 = 24.09, p < 0.01) and 14‐day VA dual therapy (χ 2 = 11.87, p < 0.01). The adverse events rate of VA dual therapy was lower than vonoprazan triple therapy (24.6% vs. 30.9%, p = 0.01) and bismuth‐containing quadruple therapy (20.5% vs. 47.9%, p < 0.01). No significant difference of compliance was observed between VA dual therapy and each subgroup. Conclusion VA dual therapy, a novel regimen, showed high efficacy as the first‐line treatment for H. pylori eradication, which should be optimized before application in different regions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
善学以致用应助71采纳,获得10
1秒前
yydragen应助樱悼柳雪采纳,获得30
1秒前
shinn发布了新的文献求助30
1秒前
Owen应助mayberichard采纳,获得10
3秒前
传奇3应助要减肥含灵采纳,获得10
3秒前
Akim应助自由的铃铛采纳,获得10
3秒前
wjx发布了新的文献求助10
4秒前
城南完成签到 ,获得积分10
4秒前
Xiaozhe完成签到,获得积分10
4秒前
淡定的雁玉完成签到 ,获得积分10
4秒前
5秒前
orixero应助666采纳,获得10
6秒前
烟花应助qiaokizhang采纳,获得10
6秒前
小蘑菇应助可耐的黄豆采纳,获得10
6秒前
让地球种满香菜完成签到,获得积分10
6秒前
7秒前
领导范儿应助shinn采纳,获得10
8秒前
9秒前
思源应助Doreen采纳,获得10
9秒前
周周完成签到 ,获得积分10
9秒前
大金鱼完成签到 ,获得积分10
10秒前
叶克思完成签到,获得积分10
10秒前
zzz完成签到,获得积分10
10秒前
刘仁轨发布了新的文献求助10
11秒前
11秒前
朱凌霄给朱凌霄的求助进行了留言
11秒前
12秒前
酷波er应助半夏彗采纳,获得10
13秒前
13秒前
shinysparrow应助挖掘机采纳,获得100
13秒前
老实憨厚的笑笑完成签到,获得积分10
14秒前
14秒前
14秒前
孙琳发布了新的文献求助10
15秒前
obcx完成签到,获得积分10
16秒前
桐桐应助wjx采纳,获得10
16秒前
variant完成签到,获得积分20
16秒前
陈依晴发布了新的文献求助10
17秒前
17秒前
wdlc发布了新的文献求助20
17秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975165
求助须知:如何正确求助?哪些是违规求助? 3519595
关于积分的说明 11198781
捐赠科研通 3255912
什么是DOI,文献DOI怎么找? 1798001
邀请新用户注册赠送积分活动 877343
科研通“疑难数据库(出版商)”最低求助积分说明 806298